undefined undefined
NaN.000
NaN.00%
Cantor Fitzgerald analyst Jennifer Kim reiterates Belite Bio (NASDAQ:BLTE) with a Overweight.
05-15 22:57
Belite Bio press release (NASDAQ:BLTE): Q1 net loss of $7.9 million. Research and development expenses were $6.8 million. General and administrative expenses were $1.6 million. As of March 31, 2024, t...
05-15 04:37
Belite Bio, Inc. ADR (BLTE) has released an update. Belite Bio, Inc has entered...
04-26 19:27
Clinical-stage biopharmaceutical drug development companyBelite Bio(NASDAQ:BLTE) entered into a securities purchase agreement with an institutional investor, for the purchase and sale of up to an aggr...
04-26 17:02
Nikola上演扎空行情!股价一周狂飙57%;特朗普旗下DJT上市爆火,股价周内狂飙24%>>
03-29 22:05
Belite Bio, Inc. ADR (BLTE) has released an update. Belite Bio, Inc has announc...
03-22 20:27
12月31日,Belite Bio Inc(BLTE.US)公布财报,公告显示公司2023财年净利润为-31.63百万美元,同比减少150.04%;其中营业收入...
03-13 07:18
Key Insights Using the 2 Stage Free Cash Flow to Equity, Belite Bio fair valu...
01-10 09:26
Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.
2023-11-14 21:23